These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 26514756)
1. Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs. Riedl M; Truyen U; Reese S; Hartmann K Vet Rec; 2015 Dec; 177(23):597. PubMed ID: 26514756 [TBL] [Abstract][Full Text] [Related]
2. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs. Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104 [TBL] [Abstract][Full Text] [Related]
3. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus. Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters. Litster A; Nichols J; Volpe A Vet Microbiol; 2012 May; 157(1-2):86-90. PubMed ID: 22261239 [TBL] [Abstract][Full Text] [Related]
5. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778 [TBL] [Abstract][Full Text] [Related]
6. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b). Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195 [TBL] [Abstract][Full Text] [Related]
7. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c. Siedek EM; Schmidt H; Sture GH; Raue R Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055 [TBL] [Abstract][Full Text] [Related]
8. Antibody levels and protection to canine parvovirus type 2. Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392 [TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose. Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. De Cramer KG; Stylianides E; van Vuuren M Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542 [TBL] [Abstract][Full Text] [Related]
11. Maternally-derived antibodies in pups and protection from canine parvovirus infection. Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665 [TBL] [Abstract][Full Text] [Related]
12. Duration of serological response to canine parvovirus-type 2, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia. Mitchell SA; Zwijnenberg RJ; Huang J; Hodge A; Day MJ Aust Vet J; 2012 Dec; 90(12):468-73. PubMed ID: 23186088 [TBL] [Abstract][Full Text] [Related]
13. Early protection of puppies against canine parvovirus: a comparison of two vaccines. McCaw DL; Tate D; Dubovi EJ; Johnson JC J Am Anim Hosp Assoc; 1997; 33(3):244-50. PubMed ID: 9138235 [TBL] [Abstract][Full Text] [Related]
14. Serological survey of canine parvovirus 2 antibody titres in breeding kennels in northern Italy. Rota A; Dogliero A; Muratore E; Pregel P; Del Carro A; Masoero L BMC Vet Res; 2019 Sep; 15(1):335. PubMed ID: 31533724 [TBL] [Abstract][Full Text] [Related]
15. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Larson LJ; Schultz RD Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247 [TBL] [Abstract][Full Text] [Related]
16. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus. Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266 [TBL] [Abstract][Full Text] [Related]
17. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. Larson LJ; Schultz RD Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379 [TBL] [Abstract][Full Text] [Related]
18. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Larson LJ; Schultz RD Vet Ther; 2007; 8(4):305-10. PubMed ID: 18183549 [TBL] [Abstract][Full Text] [Related]
19. Oral administration of modified live canine parvovirus type 2b induces systemic immune response. Cavalli A; Desario C; Marinaro M; Losurdo M; Camero M; Decaro N; Catella C; Lanave G; Buonavoglia C Vaccine; 2020 Jan; 38(2):115-118. PubMed ID: 31628031 [TBL] [Abstract][Full Text] [Related]
20. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]